News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chelsea Therapeutics, Inc. (CHTP) Blues: FDA Reviewer Still Finds Problems With Fainting Drug Northera


1/10/2014 7:37:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A treatment developed by Chelsea Therapeutics International Ltd for a rare type of low blood pressure is presenting problems for U.S. drug reviewers at the U.S. Food and Drug Administration. A review, posted on the FDA's website on Friday, comes ahead of a meeting on Jan. 14 of outside medical experts who will discuss the drug and recommend whether it should be approved. The FDA generally follows the advice of its advisory panels. The drug, droxidopa, is designed to treat neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that occurs on standing.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES